Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(0.91)
# 3,744
Out of 4,876 analysts
137
Total ratings
26.45%
Success rate
-25.25%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $10 | $3.69 | +171.37% | 1 | Jun 18, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | $42 | $14.00 | +200.00% | 9 | Jun 17, 2025 | |
| LYRA Lyra Therapeutics | Maintains: Neutral | $2 → $16 | $13.38 | +19.58% | 8 | Jun 10, 2025 | |
| PHAT Phathom Pharmaceuticals | Reiterates: Buy | $20 | $9.55 | +109.42% | 10 | Jun 9, 2025 | |
| AKBA Akebia Therapeutics | Assumes: Buy | $8 | $3.74 | +113.90% | 1 | Jun 4, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $10 | $3.81 | +162.47% | 5 | May 29, 2025 | |
| UBX Unity Biotechnology | Downgrades: Neutral | $4 → $2 | $0.79 | +154.78% | 9 | May 27, 2025 | |
| TARS Tarsus Pharmaceuticals | Assumes: Buy | $72 | $40.29 | +78.73% | 1 | May 27, 2025 | |
| ALDX Aldeyra Therapeutics | Reiterates: Buy | $10 | $3.87 | +158.40% | 13 | May 19, 2025 | |
| ZBIO Zenas BioPharma | Reiterates: Buy | $30 | $10.15 | +195.57% | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.49 | +1,104.82% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $8.28 | +286.47% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $30.11 | +26.20% | 5 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $0.71 | +1,307.66% | 4 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $0.71 | +1,585.39% | 4 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $1.02 | +684.31% | 3 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $1.95 | +2.56% | 6 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 | $3.78 | -20.63% | 4 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.41 | -41.35% | 7 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $2 | $7.89 | -74.65% | 16 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $4.07 | +784.52% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $298.93 | -90.63% | 1 | Aug 22, 2023 |
Ardelyx
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $3.69
Upside: +171.37%
Mineralys Therapeutics
Jun 17, 2025
Reiterates: Buy
Price Target: $42
Current: $14.00
Upside: +200.00%
Lyra Therapeutics
Jun 10, 2025
Maintains: Neutral
Price Target: $2 → $16
Current: $13.38
Upside: +19.58%
Phathom Pharmaceuticals
Jun 9, 2025
Reiterates: Buy
Price Target: $20
Current: $9.55
Upside: +109.42%
Akebia Therapeutics
Jun 4, 2025
Assumes: Buy
Price Target: $8
Current: $3.74
Upside: +113.90%
DiaMedica Therapeutics
May 29, 2025
Reiterates: Buy
Price Target: $10
Current: $3.81
Upside: +162.47%
Unity Biotechnology
May 27, 2025
Downgrades: Neutral
Price Target: $4 → $2
Current: $0.79
Upside: +154.78%
Tarsus Pharmaceuticals
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $40.29
Upside: +78.73%
Aldeyra Therapeutics
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $3.87
Upside: +158.40%
Zenas BioPharma
May 16, 2025
Reiterates: Buy
Price Target: $30
Current: $10.15
Upside: +195.57%
May 15, 2025
Reiterates: Buy
Price Target: $30
Current: $2.49
Upside: +1,104.82%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $8.28
Upside: +286.47%
May 8, 2025
Reiterates: Buy
Price Target: $38
Current: $30.11
Upside: +26.20%
May 1, 2025
Reiterates: Buy
Price Target: $10
Current: $0.71
Upside: +1,307.66%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $0.71
Upside: +1,585.39%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $1.02
Upside: +684.31%
Mar 31, 2025
Reiterates: Neutral
Price Target: $2
Current: $1.95
Upside: +2.56%
Mar 31, 2025
Reiterates: Neutral
Price Target: $3
Current: $3.78
Upside: -20.63%
Mar 25, 2025
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.41
Upside: -41.35%
Mar 21, 2025
Reiterates: Neutral
Price Target: $2
Current: $7.89
Upside: -74.65%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $4.07
Upside: +784.52%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $298.93
Upside: -90.63%